Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907.
To study the 5-HT(2A) receptors in the living human brain, using positron emission tomography (PET), two selective radiotracers are currently in use: [(18)F]altanserin and [(11)C]MDL 100907. It is, however, currently unknown to what extent data obtained with either tracer are directly comparable. The aim of this study was to compare binding characteristics of these two radiotracers in rat brain with respect to affinity (K(d)), receptor binding density (B(max)), binding potential (BP), and nonspecific binding. Further, binding kinetics, sensitivity towards competition with the endogenous transmitter serotonin, and the competitive/noncompetitive interaction between the two radioligands were evaluated. In addition, the selectivity of [(18)F]altanserin for the 5-HT(2A) receptor was assessed. The K(d) value of [(18)F]altanserin and [(3)H]MDL 100907 was in the order of 0.3 nM. B(max) in frontal cortex was 523 and 527 fmol/mg protein, respectively. The binding of [(18)F]altanserin was not influenced by blocking either the 5-HT(2B/2C) or the alpha(1)-adrenergic receptors. At 37 degrees C the association t(1/2) was 2.8 and 2.7 min and the dissociation t(1/2) was 11 and 13.5 min for [(18)F]altanserin and [(3)H]MDL 100907, respectively. Both radioligands were displaced by 5-HT, only at high concentrations; the K(i) value of 5-HT ranging between 650 and 3,300 nM. This indicates that binding of both radioligands in PET studies is not directly influenced by changes in endogenous 5-HT.Overall, the binding of [(18)F]altanserin and [(3)H]MDL 100907 to the 5-HT(2A) receptor was very comparable, showing selective high affinity binding in the subnanomolar range.
Kristiansen
Heidi
H
Neurobiology Research Unit, University Hospital Rigshospitalet, Copenhagen, Denmark.
Elfving
Betina
B
Plenge
Per
P
Pinborg
Lars H
LH
Gillings
Nic
N
Knudsen
Gitte M
GM
D000818:Animals; D001667:Binding, Competitive; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism*; D002250:Carbon Radioisotopes / Q000493:pharmacokinetics; D005462:Fluorine Radioisotopes / Q000493:pharmacokinetics; D005464:Fluorobenzenes / Q000493:pharmacokinetics*; D007650:Ketanserin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D008297:Male; D010880:Piperidines / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging; D051381:Rats; D017207:Rats, Sprague-Dawley; D058830:Serotonin 5-HT2 Receptor Antagonists; D012702:Serotonin Antagonists / Q000493:pharmacokinetics*
D002250:Carbon Radioisotopes; D005462:Fluorine Radioisotopes; D005464:Fluorobenzenes; D010880:Piperidines; D058830:Serotonin 5-HT2 Receptor Antagonists; D012702:Serotonin Antagonists; C071983:altanserin; D007650:Ketanserin; C079049:volinanserin